Status:
COMPLETED
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Malignant Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is giv...
Eligibility Criteria
Inclusion
- The key inclusion criteria include but are not limited to the following:
- Has histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report who have experienced disease progression on or after prior anti-cancer treatments, or been intolerant to, or refused all treatment known to confer clinical benefit
- Has head and neck squamous cell carcinoma (HNSCC), melanoma (cutaneous), non-small cell lung cancer (NSCLC), cervical cancer, triple negative breast cancer (TNBC), urothelial carcinoma (UC), or renal cell carcinoma (RCC; clear cell, papillary)
- If human immunodeficiency virus (HIV) infected, must have well controlled HIV on antiretroviral therapy (ART)
- Has normal cardiac function
Exclusion
- The key exclusion criteria include but are not limited to the following:
- If HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy
- Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids
- Has current pneumonitis/interstitial lung disease
- Has active infection requiring systemic therapy
- Has known history of Hepatitis B (defined as Hepatitis B surface antigen reactive) or known active Hepatitis C virus infection
- Has had an allogeneic tissue/solid organ transplant in the last 5 years
Key Trial Info
Start Date :
April 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 24 2025
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT06894771
Start Date
April 23 2025
End Date
November 24 2025
Last Update
December 11 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301)
Hackensack, New Jersey, United States, 07601
2
NEXT Oncology ( Site 0300)
San Antonio, Texas, United States, 78229
3
Princess Margaret Cancer Center ( Site 0101)
Toronto, Ontario, Canada, M5G 2M9
4
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102)
Québec, Quebec, Canada, G1J 1Z4